Phase i study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 6, 2013, Pages 1645-1655

  Yamamoto, Noboru ^a   Nokihara, Hiroshi ^a   Yamada, Yasuhide ^a   Uenaka, Kazunori ^b   Sekiguchi, Risa ^b   Makiuchi, Takeshi ^b   Slapak, Christopher A ^b   Benhadji, Karim A ^c   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b ELI LILLY AND COMPANY   (United States)

^c Lilly France   (France)

Author keywords

Gemcitabine prodrug; Pharmacogenetics; Pharmacokinetics; Phase I study; Solid tumors

Indexed keywords

GEMCITABINE; LY 2334737; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; COUGHING; CREATININEMIA; DEHYDRATION; DIARRHEA; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE LIMITING TOXICITY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERAMMONEMIA; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOTHERMIA; HYPOXIA; JAPAN; JAPANESE; KIDNEY DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTOSIS; LIVER FAILURE; LIVER TOXICITY; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MONOCYTOSIS; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NEUTROPHILIA; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; POLLAKISURIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEINURIA; PROTHROMBIN TIME; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; STOMACH ULCER; THROMBOCYTOPENIA; THYMUS CANCER; THYROID CARCINOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY; UPPER RESPIRATORY TRACT INFECTION; UREA BLOOD LEVEL; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; AGED; CARBOXYLESTERASE; DEOXYCYTIDINE; DEOXYURIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRODRUGS;

EID: 84878662338     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2165-2     Document Type: Article

References (28)

1. Gemzar Summary of Product Characteristics, 31 August 2011. http://www.medicines.ie/medicine/8346/SPC/Gemzar/. Accessed 11 Feb 2013
2. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W (1990) Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 50:6823-6826
3. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS (2001) Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19:3483-3489
4. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408
5. Gandhi V, Plunkett W, Du M, Ayres M, Estey EH (2002) Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 20:665-673
6. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN et al (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498
7. Sakamoto H, Kitano M, Suetomi Y, Takeyama Y, Ohyanagi H, Nakai T, Yasuda C, Kudo M (2006) Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial. J Gastroenterol 41:70-76
8. Takahashi Y, Mai M, Sawabu N, Nishioka K (2005) A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer. Pancreas 30:206-210
9. Pratt SE, Durland-Busbice S, Shepard RL, Donoho GP, Starling J, Wickremsinhe ER Mr, Perkins EJ, Dantzig AH (2013) Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts. Mol Cancer Ther 12:481-490
10. Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, Kloeker-Rhoades S, Andre VA, Beijnen JH, Slapak CA, Schellens JH (2008) Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res 14:3477-3486
11. Shipley LA, Brown TJ, Cornpropst JD, Hamilton M, Daniels WD, Culp HW (1992) Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 20:849-855
12. Moysan E, Bastiat G, Benoit J-P (2013) Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications. Mol Pharm 10:430-444
13. Bender DM, Bao J, Dantzig AH, Diseroad WD, Law KL, Magnus NA, Peterson JA et al (2009) Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J Med Chem 52:6958-6961
14. Koolen SL, Witteveen PO, Jansen RS, Langenberg MH, Kronemeijer RH, Nol A, Garcia-Ribas I, Callies S, Benhadji KA, Slapak CA, Beijnen JH, Voest EE, Schellens JH (2011) Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin Cancer Res 17:6071-6082
15. Pratt SE, Durland-Busbice S, Shepard RL, Heinz-Taheny K, Iversen PW, Dantzig AH (2013) Human carboxylesterase 2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res 19:1159-1168
16. Pratt SE, Durland-Busbice S, Shepard RL, Heinz-Taheny K, Iversen PW, Dantzig AH (2010) Identification of carboxylesterase 2 as a hydrolase that cleaves the prodrug of gemcitabine LY2334737. Abstr Clin Cancer Res 16(14 Suppl):B36
17. Xu G, Zhang W, Ma MK, McLeod HL (2002) Human Carboxylesterase 2 Is Commonly Expressed in Tumor Tissue and Is Correlated with Activation of Irinotecan. Clin Cancer Res 8:2605-2611
18. Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101:708-720
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
20. Veltkamp SA, Hillebrand MJ, Rosing H, Jansen RS, Wickremsinhe ER, Perkins EJ, Schellens JH, Beijnen JH (2006) Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. J Mass Spectrom 41:1633-1642
21. Wickremsinhe ER, Lutzke BS, Jones BR, Schultz GA, Freeman AB, Pratt SE, Bones AM, Ackermann BL (2010) Quantification of gemcitabine incorporation into human DNA by LC/MS/MS as a surrogate measure for target engagement. Anal Chem 82:6576-6583
22. Ministry of Health, Labour and Welfare of Japan (MHLW). Pharmaceuticals and medical devices safety information [MHLW Web site] [in Japanese]. http://www1.mhlw.go.Jp/houdou/1205/h05261-a-15.html#12. Accessed 10 June 2008
23. Ichikawa T, Sato H, Kaira K, Oh-I S, Kakizaki S, Sato K, Takagi H, Mori M (2008) Prolonged intrahepatic cholestasis after exposure to loxoprofen. Clin Ther 30:2402-2406
24. Veltkamp SA, Pluim D, van Eijndhoven MA, Bolijn MJ, Ong FH, Govindarajan R, Unadkat JD, Beijnen JH, Schellens JH (2008) New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′- difluorodeoxyuridine. Mol Cancer Ther 7:2415-2425
25. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, Saito Y, Ozawa S, Sawada J, Kamatani N, Furuse J, Ishii H, Yoshida T, Ueno H, Okusaka T, Saijo N (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: The impact of a cytidine deaminase polymorphism. J Clin Oncol 25:32-42
26. Holzer TR, Heinz-Taheny K, Ballard DW, Powell EL, Dolled-Filhart MP, Christiansen J, Gustavson M, Biryukov J, Virayah J, Pratt SE, Shepard RL, Durland-Busbice SC, Dantzig AH (2010) Potential for patient tailoring for prodrug of gemcitabine (LY2334737) by assessment of carboxylesterase II expression in solid tumor biopsies. Abstr Clin Cancer Res 16(14 Suppl):B31
27. Faivre S, Olszanski A, Weigang-Koehler K, Riess H, Peng G, Callies S, Benhadji KA, Raymond E (2012) Phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study of LY2334737, an oral gemcitabine prodrug, in patients (pts) with advanced solid tumors. Abstr J Clin Oncol 30(suppl):abstr 2554
28. Stuurman FE, Voest EE, Awada A, Witteveen PO, Bergeland T, Hals PA, Rasch W, Schellens JH, Hendlisz A (2013) Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors. Invest New Drugs (Epub ahead of print)